After undergoing a maze procedure and left atrial appendage (LAA) closure, can I discontinue apixaban (Eliquis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Discontinuing Apixaban After Maze Procedure and LAA Closure

After undergoing a maze procedure with left atrial appendage (LAA) closure, you should continue oral anticoagulation for at least 3 months post-procedure, then discontinuation can be considered only if you maintain sustained sinus rhythm AND have a low stroke risk (CHADS₂ score <2 or CHA₂DS₂-VASc score 0-1). However, the decision requires careful evaluation beyond just risk scores.

Post-Procedure Anticoagulation Protocol

Initial 3-Month Period:

  • All patients should receive oral anticoagulation (warfarin or apixaban) for at least 3 months after the maze procedure, regardless of rhythm status 1
  • This period allows for healing of ablated tissue and resolution of thrombogenic endothelial damage
  • The LAA closure device itself requires time for endothelialization

Criteria for Considering Discontinuation

After the initial 3-month period, evaluate ALL of the following:

1. Rhythm Status (Most Critical Factor)

  • Sustained sinus rhythm documented on multiple ECGs and/or ambulatory monitoring
  • If AF recurs at any point, continue anticoagulation indefinitely 1
  • Note: Asymptomatic AF episodes can persist even after apparently successful ablation 2

2. Stroke Risk Assessment

The guidelines provide conflicting recommendations:

  • Canadian guidelines 1: Discontinue OAC only if CHADS₂ score <2 in presence of sustained sinus rhythm
  • However, research evidence 3 demonstrates this approach is insufficient - the decision should NOT be based solely on CHADS₂ scores

3. LAA Closure Verification

  • Obtain transesophageal echocardiography (TEE) to confirm successful LAA closure 4
  • Successful closure defined as: maximal stump depth <1.0 cm without distal leak
  • If leak >5mm detected, continue anticoagulation 5
  • Among patients with confirmed successful LAA closure, 67% were able to discontinue anticoagulation 4

4. Bleeding Risk Assessment

  • High bleeding risk (HAS-BLED score ≥3) favors discontinuation if other criteria met
  • History of major bleeding episodes supports discontinuation 6

Evidence-Based Decision Algorithm

Step 1: Continue apixaban for minimum 3 months post-procedure

Step 2: At 3-6 months, obtain:

  • Multiple ECGs or extended ambulatory monitoring
  • TEE to verify LAA closure success
  • Calculate CHA₂DS₂-VASc and HAS-BLED scores

Step 3: Discontinuation is reasonable if ALL criteria met:

  • Documented sustained sinus rhythm (no AF episodes)
  • Successful LAA closure on TEE (stump <1 cm, no significant leak)
  • CHA₂DS₂-VASc score 0-1 (men 0, women 1)
  • No other indication for anticoagulation (mechanical valve, recent stroke)

Step 4: If ANY of the following present, CONTINUE anticoagulation:

  • Any documented AF recurrence
  • CHA₂DS₂-VASc ≥2 in men or ≥3 in women
  • Unsuccessful LAA closure or leak >5mm
  • Heart failure with reduced ejection fraction
  • Valvular AF
  • Recent stroke/TIA (<3 months)

Critical Caveats

The maze procedure with LAA closure does NOT automatically eliminate stroke risk 3. Research shows that among 691 patients after Cox-Maze with LAA management, stroke/TIA occurred at 5.1 cases per 1,000 person-years despite the procedure 3.

Key pitfall: The long-term stroke risk after surgical LAA procedures "appears to be low, but the requirement for long-term OAC is unclear" 1. The evidence base consists primarily of case series without large controlled trials.

Recent high-quality evidence 7: The OPTION trial (2024) demonstrated that LAA closure after AF ablation was noninferior to oral anticoagulation for preventing death, stroke, or systemic embolism at 36 months, supporting that LAA closure can be an alternative to continued anticoagulation in selected patients.

Practical Recommendation

For most patients: Continue apixaban for at least 3-6 months, then obtain TEE and rhythm assessment. Discontinuation requires documented sinus rhythm, successful LAA closure, AND low stroke risk. When in doubt, continue anticoagulation - the bleeding risk from apixaban must be weighed against stroke risk on an individual basis, considering that rhythm status and echocardiographic findings are more important than CHADS₂ scores alone 3.

Consultation with your cardiac surgeon and electrophysiologist is essential - they should provide center-specific guidance based on their surgical technique and outcomes 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.